1 / 33

BEST

BEST. Evaluation of Proposed FDA Criteria for Evaluation of Radiolabeled Red Cell Recovery Trials Larry J. Dumont, MBA, PhD James P. AuBuchon, MD for the Biomedical Excellence for Safer Transfusion (BEST) Collaborative. Blood Products Advisory Committee Rockville, MD May 1, 2008.

ajay
Download Presentation

BEST

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. BEST Evaluation of Proposed FDA Criteria forEvaluation of Radiolabeled Red Cell Recovery TrialsLarry J. Dumont, MBA, PhDJames P. AuBuchon, MDfor the Biomedical Excellence for Safer Transfusion (BEST) Collaborative Blood Products Advisory Committee Rockville, MD May 1, 2008 TRANSFUSION online: 22-Feb-2008 doi: 10.1111/j.1537-2995.2008.01642.x.

  2. Conflicts of Interest • Consultant • Gambro BCT • bioMérieux • BCSI • Verax Biomedical • Research support DHMC • Cerus • Fenwal • Gambro BCT • Haemonetics • Immunetics • Navigant Biotechnologies • Verax Biomedical • Travel Support • FDA

  3. FDA - RBC Performance Criteria • In vitro – e.g., hemolysis and ATP • In vivo - autologous 24 hour recovery • In vivo - clinical outcome (safety trials)

  4. FDA - RBC Performance Criteria • In vitro – e.g., hemolysis and ATP • In vivo - autologous 24 hour recovery • In vivo - clinical outcome (safety trials)

  5. Mean 24h recovery ≥ 75% (FDA Workshop, April 25, 1985) Mean 24h recovery ≥ 75% -and-SD  9% (FDA 1998) Background: FDA Requirements Mean 24h recovery ≥ 70% (Ross et al. JCI 1947;26:687-703)

  6. FDA Requirements Mean recovery  75% - and – SD  9% - and – LCL95%for population proportion of successes ( 75%) > 70% BPAC, July, 2004 “Success Threshold” 21 successes out of 24 18 successes out of 20

  7. % % % % % % % % % % % % % % % % % IT WILL BE OK % % % % % % % % CAUTION % % % % % % % % % % %

  8. OK Radiolabeled Red Cell Recovery – circa 1970

  9. OK Radiolabeled Red Cell Recovery – circa 1985

  10. OK min & max Radiolabeled Red Cell Recovery – circa late 1990s

  11. Individual recoveries < 75% are FAILURES Radiolabeled Red Cell Recovery – circa 2004

  12. Implication Test RBC must have  90.3% “success” for an 80% chance of passing an in vivo recovery trial • What is the clinical evidence? • What is the capability of current RBC products?

  13. Our Conclusion after review of the evidence A success threshold of 67-70% will provide a reasonable probability of passing the FDA-proposed criteria for RBC products in current use in the United States

  14. Objective Define the ability of currently available Red Blood Cell (RBC) collection and storage systems to satisfy new RBC in vivo recovery criteria proposed by the FDA for approval of RBC systems.

  15. Methods Study 9987 24h Recovery CONTROL TEST 78.2% 80.3% 82.1 79.4 80.7 77.3 … … Study 9987 24h Recovery CONTROL TEST 78.2% 80.3% 82.1 79.4 80.7 77.3 … … Study 9987 24h Recovery CONTROL TEST 78.2% 80.3% 82.1 79.4 80.7 77.3 … … ● ● ● Study 7985 24h Recovery CONTROL TEST 78.2% 80.3% 82.1 79.4 80.7 77.3 … … Study 7985 24h Recovery CONTROL TEST 78.2% 80.3% 82.1 79.4 80.7 77.3 … … Study 7985 24h Recovery CONTROL TEST 78.2% 80.3% 82.1 79.4 80.7 77.3 … … Study 345 24h Recovery CONTROL TEST 78.2% 80.3% 82.1 79.4 80.7 77.3 … … Study 345 24h Recovery CONTROL TEST 78.2% 80.3% 82.1 79.4 80.7 77.3 … … Study 345 24h Recovery CONTROL TEST 78.2% 80.3% 82.1 79.4 80.7 77.3 … … ● ● ● ● ● ● Study 134 24h Recovery CONTROL TEST 78.2% 80.3% 82.1 79.4 80.7 77.3 … … Study 134 24h Recovery CONTROL TEST 78.2% 80.3% 82.1 79.4 80.7 77.3 … … Study 134 24h Recovery CONTROL TEST 78.2% 80.3% 82.1 79.4 80.7 77.3 … … Study 12345 24h Recovery CONTROL TEST 78.2% 80.3% 82.1 79.4 80.7 77.3 … … Study 12345 24h Recovery CONTROL TEST 78.2% 80.3% 82.1 79.4 80.7 77.3 … … Study 12345 24h Recovery CONTROL TEST 78.2% 80.3% 82.1 79.4 80.7 77.3 … … LAB 1 LAB 2 LAB 11 ● ● ● ● ● ● Data review and cleaning Approved/cleared methods 1990-2006 Central Database Data verification by Sponsors n=12

  16. Methods Sample with replacement n=24 N=5000 Liquid Stored (42 days) Central Database Gamma Irradiated (28 days post) Sample with replacement n=24 N=5000 Frozen, deglycerolized (15-30 days) FDA/CBER Sample with replacement n=24 N=5000

  17. Evaluable RBC Recoveries 1990 - 2006

  18. 67%, 70%, 75% One Sample Replicate LAB ASC Rec <70% 257 1 1 64.20 1 257 1 1 71.60 0 257 1 1 70.20 0 257 1 1 79.30 0 257 1 1 76.70 0 257 1 1 93.50 0 257 1 1 73.40 0 257 1 1 85.53 0 257 1 1 71.14 0 257 2 1 81.04 0 257 2 1 66.85 1 257 2 1 77.13 0 257 2 1 84.04 0 257 2 1 81.85 0 257 2 1 77.68 0 257 2 1 80.49 0 257 2 1 58.09 1 257 2 1 82.71 0 257 2 3 40.32 1 257 2 3 83.42 0 257 2 3 75.44 0 257 2 5 73.69 0 257 2 5 74.95 0 257 2 5 74.26 0 Mean=74.9 X SD=10.5 X 4/24 < 70% X

  19. RESAMPLING n=24; N=5000 Failures

  20. RESAMPLING n=24; N=5000 Failures

  21. RESAMPLING n=24; N=5000 Failures

  22. Preliminary Conclusion FDA-proposed success threshold of >75% for individual recovery is unacceptable The general clinical performance for these products is adequate as proved over years of clinical practice, and certainly represents the state-of-the-art

  23. Sensitivity to Success Thresholdn=24

  24. Chance of current, state-of-the-art RBC products passing FDA-proposed criteria * ≥ 18 successes out of 20 trials

  25. Other Key Observations • Current RBC components are not different than the study population • There are differences between laboratories and/or study subjects

  26. Current Methods are not different than the study population < 75% 11.7% < 70% 4.5% 4 of 36 < 75% (11%) 1 of 36 < 70% (2.8%)

  27. There are differences between laboratories and/or study subjects

  28. Conclusions • The FDA-proposed success threshold of >75% is not validated against currently approved RBC products available in the US • Based on actual in vivo recovery performance, a success threshold of 67-70% will provide a reasonable probability of passing the FDA-proposed criteria LCL95%for population proportion of successes( 67%) > 70% • The mean and SD criteria may be applied as general guidance, but used with caution as distributions do not meet normality assumptions.

  29. Our Conclusion after review of the evidence • A success threshold of 67-70% will provide a reasonable probability of passing the FDA-proposed criteria for RBC products in current use in the United States • We should not make it unnecessarily burdensome for new innovations to enter the market

  30. Acknowledgements Study Laboratories American Red Cross, Louisville, KY Blood Center of Wisconsin, Milwaukee, WI Dartmouth-Hitchcock Medical Center, Lebanon, NH Hoxworth Blood Center, Cincinnati, OH Mayo Clinic, Rochester, NY American Red Cross, Norfolk, VA University of North Carolina, Chapel Hill, NC University of New Mexico, Albuquerque, NM University of Virginia, Charlottesville, VA Walter Reed Army Institute of Research Yale University, New Haven, CN Study Sponsors American Red Cross Baxter Baxter/Army Cutter / Pall Gambro BCT, Inc. Haemonetics / Transfusion Technologies Hemasure MacoPharma / UnitedPharma Terumo Vitex Individuals Lauren Clark Jaime Houghton Sherrie Sawyer Jose A. Cancelas Mike McAteer Yariv Sivan Tammy Corda Jeff Miripol Edward Snyder M. Dean Elfath Ed Nelson Tania VandenBroeke John Hess Leslie Rose Pamela Whitley Stein Holme Neeta Rugg

More Related